CA2280957A1
(en)
*
|
1997-02-14 |
1998-08-20 |
Leslie Orgel |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
NZ506839A
(en)
*
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6908900B2
(en)
*
|
2001-01-17 |
2005-06-21 |
Zimmer & Associates Ag |
Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
|
US7671029B2
(en)
|
1999-08-06 |
2010-03-02 |
Immupharma Sa |
Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
|
US6939693B2
(en)
|
1999-10-29 |
2005-09-06 |
Novus International, Inc. |
Enantioselective oligomerization of α-hydroxy carboxylic acids and α-amino acids
|
CA2389233A1
(en)
*
|
1999-10-29 |
2001-05-10 |
Paul K. S. Nam |
Oligomers and oligomeric segments of alpha-hydroxy carboxylic acids and alpha-amino acids
|
DE10018617A1
(en)
*
|
2000-01-13 |
2001-10-31 |
Joerg G Moser |
Cyclodextrin dimers with peptide spacer structures for detoxification of active pharmaceutical ingredients with high potential for side effects
|
CA2423850C
(en)
|
2000-10-09 |
2017-07-04 |
Isis Innovation Limited |
Therapeutic antibodies
|
US6881829B2
(en)
*
|
2002-04-26 |
2005-04-19 |
Chimeracom, L.L.C. |
Chimeric hybrid analgesics
|
JP2009508885A
(en)
|
2005-09-21 |
2009-03-05 |
7ティーエム ファーマ エイ/エス |
Y4 selective receptor agonists for therapeutic intervention
|
ATE516301T1
(en)
|
2005-09-21 |
2011-07-15 |
7Tm Pharma As |
Y2-SELECTIVE RECEPTOR AGONISTS FOR THERAPEUTIC INTERVENTIONS
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
WO2008086086A2
(en)
|
2007-01-05 |
2008-07-17 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
WO2008101017A2
(en)
|
2007-02-15 |
2008-08-21 |
Indiana Unversity Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
AU2008289441A1
(en)
|
2007-08-22 |
2009-02-26 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
CA2702289A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
JP5753779B2
(en)
|
2008-06-17 |
2015-07-22 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Glucagon analogs with improved solubility and stability in buffers at physiological pH
|
CN103641907A
(en)
|
2008-06-17 |
2014-03-19 |
印第安纳大学研究及科技有限公司 |
Glucagon/glp-1 receptor co-agonists
|
EP2300035B1
(en)
|
2008-06-17 |
2015-08-12 |
Indiana University Research and Technology Corporation |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
UA104605C2
(en)
|
2008-12-15 |
2014-02-25 |
Зіленд Фарма А/С |
Glucagon analogues
|
WO2010070252A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
ES2502218T3
(en)
|
2008-12-15 |
2014-10-03 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635531B2
(en)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
Glucagon analog
|
CA2744558A1
(en)
|
2008-12-19 |
2010-07-15 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
EP2376520B1
(en)
|
2008-12-19 |
2014-02-12 |
Indiana University Research&Technology Corporation |
Insulin analogs
|
WO2010071807A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
BRPI1006141B8
(en)
|
2009-01-12 |
2021-05-25 |
Cytomx Therapeutics Llc |
modified antibody compositions, methods of making and using the same
|
PE20120914A1
(en)
|
2009-06-16 |
2012-08-22 |
Univ Indiana Res & Tech Corp |
GIP RECEIVER ACTIVE GLUCAGON COMPOUNDS
|
CA2767792A1
(en)
|
2009-07-13 |
2011-01-20 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
MX2012008603A
(en)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
|
CN103003300B
(en)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Peptide conjugate of the receptor stimulating agents of GLP 1 and gastrin and application thereof
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
BR112012028704A2
(en)
|
2010-05-13 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
a peptide superfamily glugagon compound displaying receptor activity with nuclear hormone, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
|
CA2802485C
(en)
|
2010-06-16 |
2019-09-17 |
Indiana University Research And Technology Corporation |
Single chain insulin agonists exhibiting high activity at the insulin receptor
|
AR081975A1
(en)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
GLUCAGON ANALOGS
|
KR20130102470A
(en)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Amide based glucagon superfamily peptide prodrugs
|
US9169310B2
(en)
|
2010-06-24 |
2015-10-27 |
Zealand Pharma A/S |
Glucagon analogues
|
CA2803164C
(en)
|
2010-06-24 |
2018-08-21 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
MX2013006304A
(en)
|
2010-12-22 |
2013-07-02 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity.
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
JP6184404B2
(en)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
Glucagon / GLP-1 receptor co-agonist
|
EP3643306A3
(en)
*
|
2011-08-12 |
2020-08-26 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
US9259477B2
(en)
|
2011-11-03 |
2016-02-16 |
Zealand Pharma A/S |
GLP-1 receptor agonist peptide gastrin conjugates
|
KR20140097151A
(en)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
US9573987B2
(en)
|
2011-12-20 |
2017-02-21 |
Indiana University Research And Technology Corporation |
CTP-based insulin analogs for treatment of diabetes
|
US9120853B2
(en)
|
2012-04-27 |
2015-09-01 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
TR201815338T4
(en)
|
2012-05-03 |
2018-11-21 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods.
|
CA2877358A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
TWI608013B
(en)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
Glucagon analogues
|
CN104981251B
(en)
|
2012-09-26 |
2018-03-20 |
印第安纳大学研究及科技有限公司 |
Insulin analog dimer
|
JP6219308B2
(en)
|
2012-11-30 |
2017-10-25 |
株式会社糖鎖工学研究所 |
Glycosylation linker, compound containing glycosylation linker and physiologically active substance or salt thereof, and production method thereof
|
EP2970511B1
(en)
|
2013-03-14 |
2020-09-30 |
Indiana University Research and Technology Corporation |
Insulin-incretin conjugates
|
CA2907454C
(en)
|
2013-03-21 |
2021-05-04 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of hydantoin containing peptide products
|
DK2976325T3
(en)
|
2013-03-21 |
2017-06-06 |
Sanofi Aventis Deutschland |
SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
|
SI2994153T1
(en)
*
|
2013-05-07 |
2018-12-31 |
Merck Patent Gmbh |
Peptides and peptide-active ingredient-conjugate for renal drug-targeting
|
JP6510493B2
(en)
*
|
2013-05-07 |
2019-05-08 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Conjugates for protection from nephrotoxic active substances
|
DK3057984T3
(en)
|
2013-10-17 |
2018-10-08 |
Zealand Pharma As |
ACYLED GLUCAGON ANALOGS
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
CN105829339B
(en)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
glucagon-GLP-1-GIP triple agonist compounds
|
JP6682432B2
(en)
|
2013-11-06 |
2020-04-15 |
ジーランド ファーマ アクティーゼルスカブ |
GIP-GLP-1 dual agonist compounds and methods
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
US10232020B2
(en)
|
2014-09-24 |
2019-03-19 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
JP6701208B2
(en)
|
2014-09-24 |
2020-05-27 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
Lipidated amide insulin prodrug
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
CA2980978A1
(en)
|
2015-04-16 |
2016-10-20 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
RU2753193C2
(en)
|
2016-12-09 |
2021-08-12 |
Зилэнд Фарма А/С |
Acylated double agonists of glp-1/glp-2
|
CN111511757A
(en)
|
2017-11-17 |
2020-08-07 |
细胞凝胶制药有限责任公司 |
Polymeric agonists of mu opioid receptors
|